Research Institution Gap Funding and Accelerator Programs (GAP) Insights

Last week, the GAP Community of Action (GAP COA) convened more than 50 leaders of university-affiliated venture funds and innovation organizations from research institutions across North America, South America, Europe, and Australia for a strategic exchange exploring the evolving role of university venture funds within institutional innovation ecosystems. The discussion

Program Overview University of Melbourne spinout Fluent has secured A$2 million in seed funding to accelerate development of its minimally invasive brain-computer interface designed to restore communication for individuals with neurological disorders that impair speech. The company emerged from the University of Melbourne’s innovation ecosystem, progressing through Proof of Concept

The University of Sydney is taking a notable step in the evolution of university commercialization systems by openly seeking venture capital partners to help design and launch new funding vehicles capable of supporting the next generation of university-derived startups. The university estimates that its growing portfolio of research-based ventures will

Investment Overview CroíValve, a Trinity College Dublin spinout and clinical-stage medical device company, has expanded its Series B financing through: • $20 million Series B expansion financing • $7 million in European Innovation Council (EIC) and DTIF grant funding This brings: • Total Series B financing to $36 million •

Investment Overview Lumenai, a startup incubated through the Oxford University Innovation Startup Incubator, has secured pre-seed investment from Corpora.ai to expand commercialization of its Human Capability Indexing (HCIx) technology. Founded by Antonia Manoochehri, Lumenai has developed a behavioral intelligence platform that measures human capabilities often overlooked by traditional hiring and

Summary Research originating from Harvard University and supported by the Harvard Blavatnik Biomedical Accelerator (BBA) has helped produce one of the most promising new approaches to treating previously “undruggable” diseases. Chemical biologist Greg Verdine developed a novel technology known as stapled peptides, or helicons, that enables therapeutics to reach and